Cancer immunotherapy made great strides in 2016.
This has been another year of exciting progress in cancer immunotherapy, providing even more help and hope for patients, although it was not without its challenges.
After last year’s breakthroughs, 2016 cemented immunotherapy’s role in the future of cancer treatment, and it was recognized as the “Advance of the Year” by the American Society of Clinical Oncology.
For the first time ever, immunotherapy is now available for patients with head and neck cancer, with the approval of pembrolizumab.
One new immunotherapy―atezolizumab―was approved for advanced bladder and lung cancers. Additionally, patients with advanced melanoma and lung cancer can now receive immunotherapies as first-line treatments. This means they don’t have to wait until chemotherapy fails to receive immunotherapy. Lymphoma patients also have a new option in nivolumab.
|Read Full Article: Cancer Research Institute Blog – Advancing Immunotherapy for All Cancers – CRI|